
NAME: Blase N. Polite, MD, MPP, FASCO
INSTITUTION: University of Chicago
OPEN SEAT: Society Board of Directors Undesignated Member

A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION

Education:

2000 M.D. Indiana University School of Medicine, Indianapolis, IN
1995-1996 Post-Baccalaureate Pre-Medical Program, Goucher College, Towson, MD
1992 M.P.P. The University of Chicago Irving B. Harris School of Public Policy, Chicago, IL
1991 A.B. The University of Chicago (Public Policy Studies with General Honors), Chicago, IL

Postdoctoral Training:

2011-2012 American Society of Clinical Oncology Leadership Development Program
2003-2006 Chief Fellow, Hematology/Oncology, University of Chicago Hospitals, Chicago, IL
2000-2003 Resident, Internal Medicine, University of Chicago Hospitals, Chicago, IL

Licensure and Certification:

2006- Illinois State License
2006, 2016 Board Certified, Medical Oncology, MOC Participant

B. EMPLOYMENT AND APPOINTMENTS

2020- University of Chicago Biological Science Division
Professor of Medicine, Section of Hematology Oncology
Cancer Service Line Director Strategy and Network Development
Executive Medical Director for Cancer Accountable Care

2016-2020 University of Chicago Biological Science Division
Associate Professor of Medicine, Section of Hematology Oncology
Deputy Section Chief for Clinical Operations
Executive Medical Director for Cancer Accountable Care

2015-2016 University of Chicago Biological Science Division
Associate Professor of Medicine, Section of Hematology Oncology
Chief Quality Officer, Section of Hematology Oncology

2008-2015 University of Chicago Biological Science Division
Assistant Professor of Medicine, Section of Hematology Oncology

2006-2008 University of Chicago Biological Science Division
Instructor, Department of Medicine, Section of Hematology Oncology

1994 Office of Senator Bill Bradley, Washington, DC
Legislative Fellow for Health

1992-1995 Office of the Secretary, Dept. of Health & Human Services, Washington
Medicare/Health Reform Analyst (Presidential Management Intern)

C. PROFESSIONAL SOCIETIES, COMMITTEE ASSIGNMENTS, EDITORIAL BOARDS

Professional Memberships:

American College of Physicians, Associate Member
American Medical Society, Associate Member
American Society of Clinical Oncology, Active Member

Review and Editorial Experience:

Associate Editor -- *Journal of Clinical Oncology-Oncology Practice*
Editorial Board *Cancer*

Current Reviewer: *Journal of National Cancer Institute, Journal of Clinical Oncology, Health Affairs, Cancer Epidemiology Biomarkers and Prevention, Cancer, Archives of Internal Medicine, Journal of Oncology Practice, Clinical Colorectal Cancer, Journal of Urban Health, Journal of Behavioral Medicine.*

2020-2021 Special Editor for Journal of Oncology Practice Series on Cancer Health Equity
2018-2019, 2021 Associate Editor, journal of Oncology Practice (Relinquished to serve on ASCO Board)
2017- Co-Editor of Journal of Oncology Practice State of Cancer Care in America (SOCCA) Series
2019- Chair, American Cancer Society Cancer Control and Prevention: Health Policy and Health Services (CPHPS) Review Committee
2017-2018 Vice-Chair, American Cancer Society Cancer Control and Prevention: Health Policy and Health Services (CPHPS) Review Committee
2014-2016 American Cancer Society Cancer Control and Prevention: Health Policy and Health Services (CPHPS) Reviewer
2014 Breast Cancer Research Foundation Disparity Program Review Committee
2013 Susan G. Komen for the Cure – Disparities in Breast Cancer Outcomes: Outcomes of Specific Populations after Diagnosis review committee
2010-2013 American Society of Clinical Oncology Conquer Cancer Foundation Loan Repayment Program Grant Reviewer
2010-2012 American Cancer Society Illinois Grant Reviewer for Behavioral and Health Disparities Grants
2010 Chair of the *Understanding Racial and Ethnic Differences in Stage-Specific Breast Cancer Survival* grant review committee for the California Breast Cancer Research Program's Special Research Initiative

Clinical Practice:

Gastrointestinal Oncology-Colorectal, Anal, appendiceal, Neuroendocrine, pancreatic cancer focus

Administrative/Committee Work:

Intramural

2021 Search Committee Chair for Director of GI Oncology
2010 Search Committee, Faculty for Regional Therapeutics
2021 Search Committee, Section Chief for Emergency Medicine
2020- Chair, Cancer Service Line Quality Committee
2019- UCM Value Based Payment Incentive Subcommittee
2019- UCM Quality Committee
2016- Quality and Performance Committee of the UCM Care Network Affiliated Physicians LLC
2016- Board of Managers, UCM Care Network Affiliated Physicians LLC
2016- Deputy Section Chief for Clinical Operations; Executive Medical Director for Cancer Accountable Care (Funded)
2015-2016 Chief Quality Office, Section of Hematology/Oncology
2016- Board of Managers, UCM Care Network Affiliated Physicians LLC
2009- Member, Clinical Trial Review Committee of the University of Chicago Cancer Center
2008- Member, Cancer Committee of the University of Chicago Medical Center
2008-2011 Chair 2010-2011, University of Chicago Department of Medicine Research Day Program Committee

Regional

2016-2010 Board Member – Illinois Medical Oncology Society
2010 American Cancer Society Illinois Strategic Mission Advisory Committee
2010-2012 American Cancer Society Illinois – Special Disparity Initiative Advisory Committee

National/International

American Society of Clinical Oncology (ASCO)

2021 Physician Reviewer, Patient Centered Cancer Care Certification Pilot Program Task Force
2021 Member, PAC Advisory Council
2021-2022 Chair ASCO Clinical Practice Committee
2018-2020 Board Member
2016-2019 Inaugural Chair, ASCO State of Cancer Care in America Editorial Committee
2016-2017 Chair, American Society of Clinical Oncology Government Relations Committee
2015 Chair, ASCO Health Policy Fellowship Oversight Committee
2014 Chair, AACR-ACS-ASCO-NCI Think Tank: Charting the Future of Cancer Disparities Research
2012-2013 Chair, American Society of Clinical Oncology Health Disparities Committee
2014-2015 Chair, American Society of Clinical Oncology Government Relations Committee
2013 American Society of Clinical Oncology Payment Reform Task Force
2012 American Society of Clinical Oncology Value Task Force
2012-2016 American Society of Clinical Oncology 340B Task Force
2010-2011 Track Leader, American Society of Clinical Oncology GI-Colorectal Scientific Program Committee
2009-2012 American Society of Clinical Oncology Government Relations Committee
2008-2010 Member, American Society of Clinical Oncology GI-Colorectal Scientific Program Committee
2008-2014 Member, American Society of Clinical Oncology Health Disparities Advisory Group

Cancer and Leukemia Group B/Alliance

2011-2016 Member, Alliance Health Disparities Committee Cadre
2011-2016 Member, Alliance GI Oncology Committee
2008-2011 Co-Chair, Cancer and Leukemia Group B-Health Disparities Subcommittee

American Cancer Society

2014- American Cancer Society Cancer Control and Prevention: Health Policy and Health Services (CPHPS) Review Committee (Vice Chair 2017, 2018; Chair 2019)
2013 American Cancer Society Colorectal Roundtable Steering Committee

American Association of Cancer Research

2012 American Association for Cancer Research Science of Cancer Health Disparities Scientific Review Committee

California Breast Cancer Research Program

2011-2013 Member, Strategy Team and Scientific Editor Committee for the California Breast Cancer Research Program's Special Research Initiatives
2010-2013 Outside Scientific Advisor, *Understanding Racial and Ethnic Differences in Stage-Specific Breast Cancer Survival* project for the California Breast Cancer Research Program's Special Research Initiative

D. AWARDS AND HONORS

Awards and Honors:

2021 Bucksbaum Institute Senior Faculty Scholar
2019 Board Member of the American Society of Clinical Oncology

2018	Fellow of the American Society of Clinical Oncology (FASCO)
2015	Biological Science Division Distinguished Clinician Award
2014	University of Chicago Hematology Oncology Fellow Teaching Award
2014, 2015, 2017	Nominated Candidate for ASCO Board of Directors
2013	Nominated Candidate for ASCO Nominating Committee
2008	American Society of Clinical Oncology Career Development Award
2005	CALGB Young Investigator Award
2000	The John B. Hickman Award presented to the graduating senior who demonstrated outstanding clinical and academic competence in internal medicine, Indiana University School of Medicine
2000	AOA, Indiana University, Elected
1998	Donald D. Macchia Pharmacology Award for the top medical student in pharmacology, Northwest Center for Medical Education, Indiana University School of Medicine
1992	Presidential Management Intern, Washington, DC

E. TEACHING, MENTORSHIP AND RESEARCH

Teaching Portfolio:

For the College

Didactic

2007 – 2010	BIOS 11105: Ancestry, genetics and medicine- Understanding Disparities in Breast Cancer Outcomes and Basic Epidemiology. Co-Instructor for 2009, 2010. University of Chicago. Spring Quarter 2007, 2008, 2009. Course Director: Molly Prezeworski. Contact Hours: 10 hours
2020	PBHS 35500 1 (Spring 2020, 2021) Introduction to U.S. Health Policy and Politics- Toward a Value-Based Health System in Oncology: It's About the Drugs. Guest Lecturer. Course Director: Loren Saulsberry. Contact Hours: 3 hours

For Pritzker School of Medicine (MD)

Clinical

2008-2011	Clinical Skills 2: Physical Diagnosis Course- Faculty Preceptor. Winter and Spring 2008, 2009, 2010, 2011. Contact Hours: 10 hours
2006-	Daily Rounding including two medical students during 4-6 weeks per year on oncology inpatient service

For Graduate Medical Education

(a) Didactic

2009-2007-	Department of Medicine Morning Report Attending- Quarterly.
	Fellowship Core Curriculum Lectures- Colorectal Cancer, gastric cancer, health disparities. Yearly
2010-	Medical Oncology and Surgical Oncology Fellowship Journal Club Preceptor- GI Malignancies, Outcomes Research. Quarterly.

(b) Clinical

2006-	Daily Rounding including 4 residents during 4-6 weeks per year on oncology inpatient service
2006	Two GI oncology clinics per week (1.5 days) with 6-8 first year and senior oncology fellows between the two clinics

(c) Leadership

2009	Co-Medical Oncology Director for Surgical Oncology Fellowship Program
------	---

Mentorship:

Mandira Ray, Clinical Trial Participation and Race
2008 - 2010 Fellow (ASCO YIA Mentor)

2010 - Present Faculty Partners Health System
James Ward, Race and Cancer, Clinical Trial and Race
2009 – 2011- Fellow University of Chicago (CV#14)
2011 – Present- Assistant Professor of Medicine University of California Irvine
Keith Naylor, Race and Colon Cancer Outcomes
2009 – 2011- Fellow University of Chicago. (CV#14)
2011 – Present- Instructor and Coggeshall Awardee University of Chicago
Jonas de Souza, Cost of Cancer Care and Policy Solutions
2009 – 2012- Fellow University of Chicago (CV#8, 16)
2012 – 2016- Assistant Professor of Medicine University of Chicago
2017 – Present- Medical Officer Humana Insurance Company Kentucky
Erika Ramsdale, Geriatric Oncology and Cancer Outcomes (CV#18)
2010 – 2013- Fellow University of Chicago
2013 – 2016- Assistant Professor University of Virginia
2016 – Present- Assistant Professor University of Rochester
Amikar Sehdeh, Chemoprevention of Colon Cancer.
2011 – 2014- Fellow University of Chicago (CV#23, 24, 40)
2014 – Present- Assistant Professor of Medicine Indiana University School of Medicine
Jesse Soodalter -Patient and Physician Understanding of Mortality
2013 – 2016 Fellow University of Chicago
2016 – Present Research Fellow in Palliative Care at University of Pittsburgh Medical Center
Robert Daly-Quality of Cancer Care and Cancer Quality Metrics
2013 – 2016-Fellow University of Chicago
2016 – Present-Assistant Professor of Medicine Memorial Sloan Kettering Cancer Center
Christine Bestvina-End of Life Care/Advance Directives Implementation Science
2016 – 2017-Assistant Professor of Medicine, University of Chicago
Abiola Ibraheem-Global Health Care Disparities with Focus on Teamwork Barriers
2016 – Present-Instructor University of Chicago
Anu Neerukonda-Policy Fellow-Predictive Algorithm for Oncology Patient Admission/Readmission
2016 – Present Clinical Associate Professor, University of Chicago

Past and Current Research Support:

Ongoing

NCI Moonshot Grant (Polite and Kim CO-PI) 9/21/2018-8/31/2023

1UG3CA233229-01

ACCISIS Chicago

Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science in Chicago (ACCISIS-Chicago) is a two-phase study to examine the effectiveness and impact of a multilevel, multicomponent intervention on increasing rates of CRC screening, follow-up, and referral-to-care. This study will provide the evidence base for multilevel interventions, and best practices for how to scale up this intervention to reduce the unnecessary burden of colorectal cancer.

R01 CA182551 (Garcia-Aguilar) 01/01/14 - 12/31/19

NOA

Organ Preservation in Rectal Adenocarcinoma

The primary objective is to determine whether the use of neoadjuvant chemotherapy following chemoradiation therapy in rectal cancer can obviate the need for surgery in patients with a complete T stage response to therapy.

Role: Co-Investigator

Pending

R21-Developing a Nursing Spiritual Care Advocate Model (NSCA).

Completed 01/01/17 – 03/31/18

Coleman Foundation (Polite)

Current State Assessment and Pilot of Supportive Cancer Care Processes (Distress, Palliative, Hospice Referral and Survivorship Care) at the University of Chicago Medicine

Cycle 2 of the Coleman Foundation Supportive Oncology Initiative will help provide UCM the structure and support to analyze current supportive oncology processes, identify opportunities for expansion and improvement, and implement those improvements with guidance and support from experts - the program process design teams - who have experience implementing these services in their own institutions and have an understanding of supportive oncology guidelines and best practices. Our platform is ideal for advancing this process, especially in older ages.

Auxiliary Board Grant (Polite) 06/01/15 - 05/31/18
UCCRF

Spiritual Care Advocate Intervention

The UCCRF is funding my work on a link between cancer health disparities and religion and spirituality and development of interventions. Specifically, this grant is supporting the development of a Spiritual Care Advocate intervention to be used in patients with life expectancy of less than one year. The goal is to determine whether provision of spiritual care can reduce the use of inappropriate aggressive end of life.

P60MD003424 (Rauscher)- 01/01/11 - 05/31/15
NIH/UIC

Improving Adequacy of Colorectal Cancer Care for African Americans

The primary objective is examining racial differences in diagnosis, treatment, and survival between African American and White patients with new diagnosis colon cancer at seven urban hospitals in the Chicago area.

Role: Subcontract PI, Project 2

John Templeton Foundation (Polite) 07/01/12 - 06/30/15

The role of deferring to God's control in racial disparities in colorectal cancer

The primary objective is to determine the role of deferring versus collaborative religious coping on adherence to colon cancer therapy and to pilot an intervention aimed at developing more collaborative methods of religious coping in colon cancer patients.

Merck Investigators Study Program (Polite) 1/1/14-12/30/18

A pilot investigation to examine the effect of a multi-media, computer based tool (Talking Touchscreen) on enrollment in adult oncology-specific clinical trials at an academic medical center

Primary Objective: To use a proven and effective electronic communication strategy aimed at improving patient knowledge of available clinical trials leading to change in behavior to increased enrollment in clinical trials among minority patients and those of low health literacy

American Society of Clinical Oncology Career Development Award (PI) 7/1/08-6/30/11
Understanding racial disparities in chemotherapy receipt.

CALGB Young Investigator Award-(Polite) 3/01/05-1/01/07

Understanding Racial Differences in Outcome from Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840.

F. BIBLIOGRAPHY

Scholarship:

Original Papers

1. Polite BN, Lamont EB. Are Venous Thromboembolic Events Associated with Subsequent Breast and Colon Cancer Diagnoses in the Elderly? A Case-Control Trial of Medicare Beneficiaries. *Cancer*. 2006;106(4):923-30.
2. Polite BN, Desai AA, Peterson AC, Manchen B, Stadler WM. Combination Therapy of Imatinib Mesylate and Interferon-Alpha Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of A Single Institution Phase II Trial, *Clinical Genitourinary Cancer*. 2006;4(4):275-80.
3. Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell M, Wolmark N. Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer. *Journal of the National Cancer Institute*. 2006;98 (22):1647-54.
4. Polite BN, Cirrincione C , Fleming GF, Berry DA, Seidman AD, Muss H, Norton L, Hudis C, Winer EP. Understanding racial differences in outcome from metastatic breast cancer (MBC): A pooled analysis of Cancer and Leukemia Group B (CALGB) 9342 and 9840- *Journal of Clinical Oncology*. 2008; 26:2659-65.

5. Mell LK, Jeong JH, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of Competing Mortality in Advanced Head and Neck Cancer-*Journal of Clinical Oncology*. 2010 Jan 1;28(1):15-20.
6. Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ. Predictors of competing mortality in early breast cancer-*Cancer*. 2010;116:5365-73.
7. Ocean AJ, Polite BN, Christos P, Horvath L, Matulich D, Chen HX, Sparano JA, Kindler H. Cetuximab is Associated with Excessive Toxicity when Combined with Bevacizumab plus m-FOLFOX6 in Metastatic Colorectal Carcinoma-*Clinical Colorectal Cancer*. 2010 9:290-6.
8. De Souza JA, Polite BN, Manning WG, Fendrick AM, Ratain MJ. Value-Based Insurance Design in Oncology: Bridging Rational Drug Development, Evidence and Value. *Lancet Oncology*.2011;12:321-323.
9. Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman BG, Taber D, Vokes EE, Stadler WM, Kindler HL. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. *Investigational New Drugs*. 2012; 30:1211-5.
10. Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, Feng S. Exploring Racial Differences in Outcome for Metastatic Colorectal Cancer: Results From a Large Prospective Observational Cohort Study (BRiTE) *Cancer*. 2012; 118(4):1083-90
11. Sylvester B, Huo D, J, Smalling RV, Polite BN, Olopade OI. Comprehensive Analysis of Colorectal Tumors within a Diverse Cohort of Patients at a Single Institution. *Clin Cancer Res*. 2012;18:350-9.
12. Conti RC, Rosenthal M, Polite BN, Bach PB, Shih T. Infused chemotherapy use in the elderly following patent expiration. *Am J Manag Care*. 2012;18:e173-8.
13. Finn RS, Kang YK., Mulcahy M., Polite B. N., LimHY, Walters I, Baudelet C, Manekas D, Park, JW. Phase II, Open-label Study of Brivanib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma. *Clin Cancer Res*. 2012;18:2090-8.
14. Naylor K*, Ward J*, Polite BN. Interventions to Reduce Racial and Ethnic Disparities in Colorectal Cancer Outcomes: A Systematic Review of the Literature. *Journal of General Internal Medicine*.2012;27:1033-46
15. Tonlaar BS, Song S, Hong JC, Minsky BD, Chang DT, Polite BN, Liauw SL. Combined Modality Therapy for Rectal Cancer: Analysis of Potential Differences in Disease Presentation, Treatment Adherence, and Treatment Outcome According to Race. *Am J Clin Oncol*. 2012;37:122-5.
16. De Souza J, Polite BN, Zhu S, Dignam JJ, Meropol N, Ratain MJ, Newcomer LN, Alexander GC. Unsupported off-label chemotherapy in metastatic colon cancer. *BMC Health Services Research*. 2012; 12:481.
17. Grubbs S*, Polite BN*, Carney J, Bowser W, Rogers J, Katurakes N, Hess P, Paskett ED. Eliminating Racial Disparities in Colorectal Cancer in the Real World: It Took a Village. *J Clin Oncol*. 2013 Jun 1;31(16):1928-30.
18. Ramsdale EE, Polite BN, Bylow KA, Kindler HL, Dale W. Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older. *J Am Geriatr Soc*. 2013 Nov;61(11):2043-4.
19. Jagsi R*, Chiang A*, Polite BN*, Medeiros BC*, McNiff K, Abernethy A, Zon R, Loehrer P. A Qualitative Analysis of Practicing Oncologists' Attitudes and Experiences Regarding Collection of Patient-Reported Outcomes. *J Oncol Pract*. 2013 Nov 1;9(6):e290-7
20. Bhatta SS, Hou N, Moton ZN, Polite BN, Fleming GF, Olopade OI, Huo D, Hong S. Factors Associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. *Springerplus*. 2013;2:356.
21. Geynisman, DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci VT, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. *J Immunother Cancer*. 2013 Jun 27;1:8. doi: 10.1186/2051-1426-1-8. eCollection 2013.

22. Salgia R, Patel P, Bothos L, Yu W, Bai S, Nijem I, Catenacci D, Peterson A, Ratain M, Polite BN, Mehnert J, Moss RA. Phase 1 dose-escalation study of onartuzumab as a single agent and in a combination with bevacizumab in patients with advanced solid malignancies. *Clinical Cancer Research*. 2014;20:1666-75.
23. Sehdev A, Shih YC, Huo D, Vekhter B, Lyttle C, Polite BN. The Role of Statins for Primary Prevention in on-Elderly Colorectal Cancer Patients. *Anticancer Research*. 2014. 34(9):5043-50.
24. Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C, Lencioni R. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. *Liver Cancer*. 2014 3:439-50.
25. Sehdev A, Shih YC, Vekhter B, Bissonnette M, Olopade OI, Polite BN. Metformin for Primary Colorectal Cancer Prevention in Diabetic Patients: A Case-Control Study in a US Population. *Cancer*. 2015 Apr 1;121(7):1071-8. doi: 10.1002/cncr.29165. Epub 2014 Nov 25.
26. Aguilar JG, Chow OS, Smith DD, Marcet J, Cataldo P, Varma MG, Kumar AS, Oommen S, Coutsoftides T, Hunt S, Stamos M, Ternent CA, Herzig D, Fichera A, Polite BN, Dietz DW, Patil S, Avila K. Adding mFOLFOX-6 after neoadjuvant chemoradiation increases pathologic complete response in locally advanced rectal cancer: Results from a multicenter phase 2 trial with four sequential groups. *Lancet Oncol*. 2015 Aug;16(8):957-66. doi: 10.1016/S1470-2045(15)00004-2. Epub 2015 Jul 14.
27. O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. *Clin Cancer Res*. 2015. Epub ahead of print.
28. Polite BN, Cipriano-Steffens T, Hlubocky FJ, Dignam J, Ray M, Smith DM, Undevia S, Sprague E Olopade OI, Daugherty C, Fitchett G, Gehlert SJ. An evaluation of psychosocial and religious belief differences in a diverse racial and socioeconomic cancer population. *J Racial Ethn Health Disparities*. 2017 Apr;4(2):140-148. doi: 10.1007/s40615-016-0211-6. Epub 2016 Mar 16.
29. Lee Am, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields Af, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147. *Pharmacogenet Genomics*. 2016 Mar;26(3):133-7. doi: 10.1097/FPC.000000000000197.
30. Toffoli G, Sharma MR, Marangon E, Posocco B, Gray E, May Q, Buonadonna A, Polite BN, Miolo G, Tabaro G, Innocenti F. Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients. *Clin Cancer Res*. 2016. Aug 9. pii: clincanres.1012.2016. [Epub ahead of print]
31. Daly B, Hantel A, Wroblewski K, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. *J Oncol Pract*. 2016 Oct;12(10):e901-e911.
32. Naylor K, Fritz C, Polite BN, Kim K. Evaluating Screening Colonoscopy Quality in an Uninsured Urban Population. *Prev Med Rep*. 2016 Dec 27;5:194-199. doi: 10.1016/j.pmedr.2016.12.019.
33. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. *Lancet Oncol*. 2017 Feb 17. pii: S1470-2045(17)30104-3. doi: 10.1016/S1470-2045(17)30104-3. [Epub ahead of print]
34. O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R2, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Streck ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KJ, Leung EK, Volchenbourn SL, Altman RB, Olopade OI, Stadler WM2, Meltzer DO, Ratain M. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. *Clin Pharmacol Ther*. 2017 Apr 11. doi: 10.1002/cpt.709. [Epub ahead of print]

35. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C1, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA*. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.
36. Tseng J , Bryan DS , Poli E , Sharma M , Polite BN , Turaga KK . Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. *Lancet Oncol*. 2017 Jun;18(6):711-712. doi: 10.1016/S1470-2045(17)30336-4.
37. Jones LA, Ferrans CE, Polite BN, Brewer KC, Maker AV, Pauls HA, Rauscher GH. Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study. *Ann Epidemiol*. 2017 Nov;27(11):731-738.e1. doi: 10.1016/j.annepidem.2017.10.006. Epub 2017 Oct 13.
38. De W Marsh, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. *J Surg Oncol*. 2017 Oct 16. doi: 10.1002/jso.24872. [Epub ahead of print]
39. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui UD, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. *Cancer Discov*. 2017 Oct 4. doi: 10.1158/2159-8290.CD-17-0395. [Epub ahead of print]
40. Polite BN, Cipriano TC, Hlubocky F, Jean-Pierre P, Cheng A, Brewer A, Rauscher G, Fitchett G. Association of Religious and Spiritual Beliefs on Stage of Colon Cancer Diagnosis Among a Bi-Racial Multi-Center Urban Patient Population. *Cancer*. 2018 Mar 26. doi: 10.1002/cncr.31351. [Epub ahead of print]
41. Ward JC, Levit LA, Page RD, Hennessy JE, Cox JV, Kamin DY, Bruinooge SS, Shih YT, Polite BN. Impact on Oncology Practices of Including Drug Costs in Bundled Payments. *J Oncol Pract*. 2018;14(5):359-268.
42. Bestvina CM, Wroblewski KE, Daly B, Beach B, Chow S, Hantel A, Huber MT, Polite BN. A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. *J Palliat Med*. 2018 Mar 13. doi: 10.1089/jpm.2017.0408. [Epub ahead of print]
43. Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, Stadler WM, Ratain MJ, O'Donnell PH. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. *Cancer*. 2018 Jul 15;124(14):3052-3065. doi: 10.1002/cncr.31382. Epub 2018 May 9.
44. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9
45. Sherman SK, Lange JJ, Dahdaleh FS, Rajeev R, Gamblin TC, Polite BN, Turaga KK. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. *JAMA Oncol*. 2018 Nov 29. doi: 10.1001/jamaoncol.2018.5070. [Epub ahead of print]
46. Dahdaleh FS, Sherman SK, Poli EC, Vigneswaran J, Polite BN, Sharma MR, Catenacci DV, Maron SB, Turaga KK. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. *Surgery*. 2018 Dec;164(6):1223-1229. doi: 10.1016/j.surg.2018.06.044. Epub 2018 Oct 5.
47. Marco MR, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, Cataldo PA, Hunt SR, Kumar A, Herzig DO, Fichera A, Polite BN, Hyman NH, Ternent CA, Stamos MJ, Pigazzi A, Dietz D, Yakunina Y, Pelossof R, Garcia-Aguilar J; Timing of Rectal Cancer Response to Chemoradiation Consortium. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. *Dis Colon Rectum*. 2018 Oct;61(10):1146-1155. doi: 10.1097/DCR.0000000000001207.

48. Polite BN, Cipriano TC, Liao C, Miller E, Arndt N, Hahn EA. Investigation of a multi-media, computer-based approach to improve knowledge, attitudes, self-efficacy and receptivity to cancer clinical trials among newly diagnosed patients with diverse health literacy skills. *Cancer*. 2019 Jun 15;125(12):2066-2075. doi: 10.1002/cncr.31991. Epub 2019 Feb 27
49. Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. *J Clin Oncol*. 2019 May 10;37(14):1217-1227. doi: 10.1200/JCO.18.01798. Epub 2019 Mar 13
50. Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. *Cancer*. 2019 May 15;125(10):1629-1636. doi: 10.1002/cncr.31938. Epub 2019 Jan 15
51. Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. *Clin Cancer Res*. 2019 Sep 26. doi: 10.1158/1078-0432.CCR-19-1483. [Epub ahead of print]
52. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. *J Clin Oncol*. 2019 Oct 10;37(29):2620-2631. doi: 10.1200/JCO.19.01019. Epub 2019 Aug 13.
53. Uppal A, Smieliauskas F, Sharma MR, Maron SB, Polite BN, Posner MC, Turaga K. Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. *Cancer*. 2019 Oct 22. doi: 10.1002/cncr.32529. [Epub ahead of print]
54. Cipriano-Steffens TM, Carilli T, Hlubocky F, Quinn M, Fitchett G, Polite BN. "Let Go, Let God": A Qualitative Study Exploring Cancer Patients' Spirituality and Its Place in the Medical Setting. *J Relig Health*. 2019 Nov 8. doi: 10.1007/s10943-019-00942-3. [Epub ahead of print]
55. Carnahan LR, Jones L, Brewer KC, Watts EA, Peterson CE, Ferrans CE, Cipriano-Steffens T, Polite B, Maker AV, Chowdhery R, Molina Y, Rauscher GH. Race and Gender Differences in Awareness of Colorectal Cancer Screening Tests and Guidelines Among Recently Diagnosed Colon Cancer Patients in an Urban Setting. *Cancer Educ*. 2019 Dec 14. doi: 10.1007/s13187-019-01666-4. [Epub ahead of print]
56. Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MC. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. *JAMA Netw Open*. 2020 Feb 5;3(2):e1921290. doi: 10.1001/jamanetworkopen.2019.21290.
57. Brewer KC, Peacock NR, Ferrans CE, Campbell RT, Polite B, Carnahan L, Jones LA, Rauscher GH. Gender- and Race-Based Differences in Barriers and Facilitators to Early Detection of Colon Cancer. *J Womens Health (Larchmt)*. 2020 Feb 25. doi: 10.1089/jwh.2019.8163. [Epub ahead of print]
58. Ibraheem AF, Giurcanu M, Sowunmi AC, Awolude O, Habeebu M, Popoola A, Sanni F, Agaga LA, Olopade O, Polite BN. Formal Assessment of Teamwork Among Cancer Health Care Professionals in Three Large Tertiary Centers in Nigeria. *CO Glob Oncol*. 2020 Apr;6:560-568. doi: 10.1200/JGO.19.00233.
59. Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). *JNCI Cancer Spectr*. 2019 Oct 17;4(1):pkz078. doi: 10.1093/jncics/pkz078. eCollection 2020 PMID: 32259016

60. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Pollak MN, Nixon AB, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson AB 3rd, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. *JNCI Cancer Spectr.* 2020 Aug 27;5(1):pkaa074. doi: 10.1093/jncics/pkaa074. PMID: 33426464; PMCID: PMC7785047.
61. Van Blarigan EL, Zhang S, Ou FS, Venlo A, Ng K, Atreya C, Van Loon K, Niedzwiecki D, Giovannucci E, Wolfe EG, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. *JAMA Netw Open.* 2020 Oct 1;3(10):e2023500. doi: 10.1001/jamanetworkopen.2020.23500. PMID: 33125497; PMCID: PMC7599454.
62. Kim K, Polite BN, Hedeker D, Liebovitz D, Randal F, Jayaprakash M, Quinn M, Lee SM, Lam H. Implementing a multilevel intervention to accelerate colorectal cancer screening and follow-up in federally qualified health centers using a stepped wedge design: a study protocol. *Implement Sci.* 2020 Oct 29;15(1):96. doi: 10.1186/s13012-020-01045-4. PMID: 33121536; PMCID: PMC7599111.
63. Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. *Cancer Discov.* 2021 Feb;11(2):308-325. doi: 10.1158/2159-8290.CD-20-1408. Epub 2020 Nov 24. PMID: 33234578; PMCID: PMC7858231.
64. Berger Y, Schuitevoerder D, Vining CC, Alpert L, Fenton E, Hindi E, Liao CY, Shergill A, Catenacci DVT, Polite BN, Eng OS, Turaga KK. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. *Ann Surg Oncol.* 2021 Mar;28(3):1777-1785. doi: 10.1245/s10434-020-09064-7. Epub 2020 Sep 5. PMID: 32892267.
65. Vaghaiwalla T, Ruhle B, Memeh K, Angelos P, Kaplan E, Liao CY, Polite BN, Keutgen X. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. *Surgery.* 2021 Jan;169(1):162-167. doi: 10.1016/j.surg.2020.04.001. Epub 2020 May 20. PMID: 32446596.
66. Snyder RA, He J, Le-Rademacher J, Ou FS, Dodge AB, Zemla TJ, Paskett ED, Chang GJ, Innocenti F, Blanke C, Lenz HJ, Polite BN, Venook AP. Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). *Cancer.* 2021 Aug 10. doi: 10.1002/cncr.33649. Epub ahead of print. PMID: 34374082.
67. Cipriano-Steffens T, Cursio JF, Hlubocky F, Sumner M, Garnigan-Peters D, Powell J, Arndt N, Phillips L, Lassiter RH, Gilliam M, Petty LE, Pastor RSO, Malec M, Fitchett G, Polite B. Improving End of Life Cancer Outcomes Through Development and Implementation of a Spiritual Care Advocate Program. *Am J Hosp Palliat Care.* 2021 Mar 5:1049909121995413. doi: 10.1177/1049909121995413. Epub ahead of print. PMID: 33663241.
68. Brajcich BC, Benson AB, Gantt G, Eng OS, Marsh RW, Mulcahy MF, Polite BN, Shogan BD, Yang AD, Merkow RP. Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative. *J Surg Oncol.* 2021 Nov 25. doi: 10.1002/jso.26758. Epub ahead of print. PMID: 34820843.
69. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Pollak MN, Nixon AB, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson AB 3rd, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. *JNCI Cancer Spectr.* 2020 Aug 27;5(1):pkaa074. doi: 10.1093/jncics/pkaa074. PMID: 33426464; PMCID: PMC7785047.
70. Berger Y, Giurcanu M, Vining CC, Schuitevoerder D, Posner MC, Roggin KK, Polite BN, Liao CY, Eng OS, Catenacci DVT, Turaga KK. Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. *Ann Surg Oncol.* 2021 Aug;28(8):4433-4443. doi: 10.1245/s10434-020-09475-6. Epub 2021 Jan 8. PMID: 33420565.

71. Jones LA, Brewer KC, Carnahan LR, Parsons JA, Polite BN, Ferrans CE, Warnecke RB, Rauscher GH. Health Insurance Status as a Predictor of Mode of Colon Cancer Detection but Not Stage at Diagnosis: Implications for Early Detection. *Public Health Rep.* 2021 Mar 31;33354921999173. doi: 10.1177/0033354921999173. Epub ahead of print. PMID: 33789522.

Policy and Consensus Statements

72. Moy B*, Polite BN*, Halpern MT, McCaskill-Stevens W, Stranne SK, Winer EP, Wollins DS, Newman LA. American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities. *Journal of Clinical Oncology.* 2011 Oct 1;29(28):3816-24. Epub 2011 Aug 1.

73. Patel J, Krilov L, Adams S, Aghajanian C, Basch E, Brose M, Carroll W, de Lima M, Gilver M, Kris M, Marshall J, Masters G, O'Day S, Polite B*, Roth B, Schwartz G, Sharma S, Thompson I, Vogelzang N. Clinical Cancer Advances 2013: Annual Report On Progress Against Cancer From The American Society Of Clinical Oncology.. *Journal of Clinical Oncology.* 2014;32:129-60. (**Editor of the Health Disparities Section)

74. Policy Statement on 340B Drug Pricing by the American Society of Clinical Oncology. *Journal of Oncology Practice.* Published online before print April 15, 2014, doi: 10.1200/JOP.2014.001432 (Member of Policy writing committee).

75. Polite BN, Griggs JJ, Moy B, Lathan C, DuPont NC, Villani G, Wong SL, Halpern MT. American Society of Clinical Oncology Policy Statement on Medicaid Reform. *Journal of Clinical Oncology.* 2014;32:4162-7.

76. Polite BN, Ward JC, Cox JV, Morton RF, Hennessy J, Page R, Conti RM. Payment for Oncolytics in the United States: A History of 'Buy and Bill' and Proposals for Reform. *Journal of Oncology Practice.* 2014. 10(6):357-62.

77. Polite BN, Miller HD. The Medicare Innovation Center Oncology Care Model: A Toe in the water when a plunge is needed. *Journal of Oncology Practice.* 2015. 11(3):263-4.

78. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney D, Blum D, Dicker Ap, Ganz PA, Hoverman J, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J., Polite BN, Raghavan D, Rossi G, Saltz L, Schrag D, Smith T, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Framework to Assess the Value of Cancer Treatment Options. *Journal of Clinical Oncology.* 2015;16:957

79. Schnipper LE, Davidson NE, Wollins DS, Blayney D, Dicker Ap, Ganz PA, Hoverman J, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J., Polite BN, Raghavan D, Rossi G, Saltz L, Schrag D, Smith T, Yu PP, Hudis CA, Vose JM Schilsky RL. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. *Journal of Clinical Oncology.* 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31.

80. Polite BN, Ward JC, Cox JV, Morton RF, Hennessy J, Page R, Conti RM. A Pathway Through the Bundle Jungle. *J Oncol Pract.* 2016;12 (6):504-509

81. Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS, Li CI, Lichtenfeld JL, McCaskill-Stevens W, Paskett ED. Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Published Simultaneously: *Cancer Res.* 2017 Jul 24. doi: 10.1158/0008-5472.CAN-17-0623. [Epub ahead of print] No abstract available; *CA Cancer J Clin.* 2017 Jul 24. doi: 10.3322/caac.21404. [Epub ahead of print] No abstract available; *J Clin Oncol.* 2017 Jul 24;JCO2017736546. doi: 10.1200/JCO.2017.73.6546. [Epub ahead of print] No abstract available.

82. Polite BN, Seid JE, Levit LA, Kirkwood MK, Schenkel C, Bruinooge SS, Grubbs SS, Kamin DY, Schilsky RL. A New Look at the State of Cancer Care in America. *J Oncol Pract.* 2018 Jul;14(7):397-399. doi: 10.1200/JOP.18.00150. Epub 2018 Jun 15.

83. Kirkwood MK, Hanley A, Bruinooge SS, Garrett-Mayer E, Levit LA, Schenkel C, Seid JE, Polite BN, Schilsky RL. The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. *J Oncol Pract.* 2018 Jul;14(7):e412-e420. doi: 10.1200/JOP.18.00149. Epub 2018 Jun 15.

84. Zafar SY, Polite BN, McClellan M. Engaging Patients in Value-Based Cancer Care: A Missed Opportunity. *JAMA Oncol.* 2018 Nov 1;4(11):1479-1480. doi: 10.1001/jamaoncol.2018.2826.
85. Polite BN (lead author). American Society of Clinical Oncology Position Statement On Addressing the Affordability of Cancer Drugs. *Journal of Oncology Practice* 14, no. 3 (March 1 2018) 187-192.
86. Polite BN, Seid JE, Freeman M, Levit LA, Krkwood MK, Schenkel C, Bruinooge SS, Schilsky RL. State of Cancer Care in America: Reflections on an inaugural year. *J Oncol Pract.* 2019 Apr;15(4):163-165. doi: 10.1200/JOP.18.00746. Epub 2019 Mar 11
87. Polite BN, Gluck AR, Brawley OW. Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer. *JAMA.* 2019 Apr 8. doi: 10.1001/jama.2019.4266. [Epub ahead of print]
88. Kircher SM, Royce TJ, Upadhyay D, Polite BN. Opaque Results of Federal Price Transparency Rules and State-Based Alternatives. *J Oncol Pract.* 2019 Sep;15(9):463-464. doi: 10.1200/JOP.19.00354. Epub 2019 Aug 12
89. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Standards. *Ann Surg Oncol.* 2020 Jun;27(6):1743-1752. doi: 10.1245/s10434-020-08325-9. Epub 2020 Apr 13. PMID: 32285276.
90. Major A, Polite BN. Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will. *Cancer J.* 2020 Jul/Aug;26(4):304-310. doi: 10.1097/PPO.0000000000000458. PMID: 32732673.
91. Polite BN, Ratain MJ, Lichter AS. Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change. *JAMA Oncol.* 2021 Jan 1;7(1):25-26. doi: 10.1001/jamaoncol.2020.1828. PMID: 3300113

*Authors Contributed equally to this article.

Reviews, Commentaries, Editorials

92. Polite BN, Dignam JJ, Olopade OI. Colorectal Cancer and Race: Understanding the Differences in Outcomes between African Americans and Whites. *Medical Clinics of North America.* 2005; 89(4):771-93.
93. Polite BN, Olopade OI. Breast Cancer and Race: A rising tide does not lift all boats equally. *Perspectives in Biology and Medicine.* 2005;48(suppl 1):S166-S175.
94. Polite BN, Schilsky RL. Paying for Clinical Trials: Shared Sacrifice for a Shared Goal. *The Hematologist.*2005;2:4.
95. Polite BN, Dignam JJ, Olopade OI. A Colorectal Cancer Model of Health Disparities: Understanding Mortality Differences in Minority Populations. *Journal of Clinical Oncology.* 2006;24(14):2179-2187.
96. Ray M, Polite BN. Triple Negative Breast Cancer: A View From 10,000 Feet. *The Cancer Journal.* 2010;16:17-22.
97. Catenacci DVT, Kozloff M, Kindler HL, Polite BN. Personalized Colon Cancer Care in 2010. *Seminars in Oncology.* 2011;38:284
98. Polite BN. Reducing Disparities in Cancer Outcomes: A Call to Action. *ASCO Daily News.* June3-7, 2011. Chicago.
99. Polite BN, Sylvester BE, Olopade OI. Race and Subset Analyses in Clinical Trials: Time to Get Serious About Data Integration. *J Natl Cancer Inst.* 2011;103:1486-8.
100. Cipriano TM, Polite BN. Achieving Health Equity in Colorectal Cancer. *Am Soc of Clin Oncol Educ Book* 2013;2013:169-173.
101. Sehdev A Polite BN. Modern Chemoradiation and Chemotherapy Protocols for Locally Advanced Rectal Cancer: The Current and Future Standards of Care. *Seminars in Colon and Rectal Surgery* 2013;24:132-141
102. Zhang SQ, Polite BN. Achieving a deeper understanding of the implemented provisions of the affordable care act. *Am Soc of Clin Oncol Educ Book* 2014;34:e472-7.
103. Polite BN. The States as the laboratory for democracy: Is anybody paying attention and does anybody care? *Journal of Clinical Oncology* 2015;33(8):815-816
104. Polite BN, Conti RM, Ward JC. Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. *Am Soc Clin Oncol Educ Book* 2015:e75-80
105. Polite BN, Page R, Nabhan C. Oncology Pathways: Preventing a Good Idea from Going Bad. *JAMA Oncology* 2016 Feb 4.

106. Nabhan A, Polite BN. A Dynamic Equilibrium. *J Oncol Pract* 2017 Apr 17;JOP2016020305. doi: 10.1200/JOP.2016.020305. [Epub ahead of print].
107. Bestvina CM, Polite BN. Implementation of Advance Care Planning in Oncology: A Review of the Literature. *J Oncol Pract*. 2017 Jun 6;JOP2017021246. doi: 10.1200/JOP.2017.021246. [Epub ahead of print]
108. Polite BN, Walradt J. Pursuing Value in Cancer Care: A Model in Progress. *J Oncol Pract*. 2017 Jul;13(7):407-409. doi: 10.1200/JOP.2017.023648. Epub 2017 Jun 26
109. Ibraheem A, Polite B. Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes. *Cancer*. 2017 Dec 15;123(24):4752-4756. doi: 10.1002/cncr.31073. Epub 2017 Oct 26.
110. Polite BN. The Road from Theory to Reality: Illuminating the Complexity of Prospective Cancer Bundles. *J Oncol Practice* 2018. Feb;14(2):59-61. doi: 10.1200/JOP.2017.029090. Epub 2018 Jan 18
111. XuE L, Williamson A, Gaines S, Andolfi C, Paul-Olson T, Neerukonda A, Steinhagen E, Smith R, Cannon LM, Polite BN, Umanskiy K, Hyman N. An Update on Colorectal Cancer. *Curr Probl Surg*. 2018 Mar;55(3):76-116. doi: 10.1067/j.cpsurg.2018.02.003. Epub 2018 Feb 13.
112. Dreyer T, Wilfong LS, Patel K, Gamble B, Polite BN. Oncology Care Model: A Herculean Effort With Fixable Fatal Flaws. *JCO Oncol Pract*. 2021 Feb 4;OP2000852. doi: 10.1200/OP.20.00852. Epub ahead of print. PMID: 33539172.

Book Chapters

113. Polite BN. "Eliminating Health Disparities in Colorectal Cancer Mortality" in *Early Detection and Prevention of Colorectal Cancer*. 2009. Slack, inc.
114. Sharma M, Polite B. "Fundamentals of DNA Synthesis." In *Cancer Biology Review: A Case Based Approach*. 2013. demosMedical, New York, NY.
115. Polite BN. "Stage II Colon Cancer: Toward an Individualized Approach" 2016. Springer International Publishing Switzerland
116. Polite BN, Catenacci D. "Gastrointestinal Tumors" in *ASCO Self Evaluation Program (SEP) 7th Addition*. In Press.

Invited Presentations:

Intramural

- 2003 Grand Rounds. University of Chicago Hospitals. Venous Thromboembolism and Cancer: What do we know and what should we do about it?
- 2003 Hematology/Oncology Grand Rounds. University of Chicago Hospitals. Venous Thromboembolism and Cancer: What do we know, what should we do about it, and can we prevent the subsequent cancers?
- 2004 Hematology/Oncology Grand Rounds. University of Chicago Hospital. Breast Cancer and Race: A Rising Tide Does Not Lift All Boats Equally.
- 2004 Hematology/Oncology Grand Rounds. University of Chicago Hospital. The Rising PSA Following Definitive Therapy for Prostate Cancer: The Case for and Against Early Hormone Therapy.
- 2005 Department of Medicine Research in Progress Conference. Effect of Body Mass Index on Outcomes in Colon Cancer: An Analysis of NSABP Randomized Trials C-04 and C-05.
- 2009 Gastroenterology Grand Rounds: Treatment of Stage II and III Colon Cancer: Are We Closer To the Era of Personalized Medicine? Chicago, IL.
- 2009 University of Chicago and Northshore Health System Department of Surgery Grand Rounds: Adjuvant Chemotherapy for Colon Cancer: Have We Reached the Era of Personalized Medicine? Chicago, IL.
- 2012 University of Chicago Department of Medicine Grand Rounds. Understanding and Reducing Disparities in Colorectal and Breast Cancer: From Diagnosis Forward. Chicago, IL.

Regional

- 2007 Illinois Humanities Council- How Does Race Matter? Genetics and Race. Breast Cancer and Race-Does Genetics Matter? Chicago, IL.
- 2008 Brother to Brother Race and Cancer Symposium: Take Care of Your Colon and Your Colon Will Take Care of You. Chicago, IL.
- 2008 Grand Rounds. Little Company of Mary Hospital Cancer Center: Recent Updates in Colorectal Cancer Oncology. Evergreen Park, IL.
- 2008 Grand Rounds Loyola University Cardinal Bernadin Cancer Center- Understanding and Reducing Health Disparities in Oncology: Pick The Low Hanging Fruit. Maywood, IL

- 2008 Grand Rounds. Advocate South Suburban Hospital: Updates in Colorectal Cancer Oncology. Hazel Crest, IL.
- 2009 University of Chicago GI Cancer Symposium: Chemotherapy Vs. Chemoradiotherapy in Gastric Cancer: Will We Ever Declare a Winner? Chicago, IL.
- 2011 Controversies in the Management of Complex GI Cancer Patients: Metastatic Rectal Cancer: The More We Understand, The Less We Know. Chicago, IL.
- 2012 New Horizons in Cancer Genetics and Applications to Clinical Practice: Prevention of Colorectal Cancer in High Risk Individuals: Doc What Else Can I Do? Chicago, IL
- 2012 4th Annual Gastrointestinal Cancer Symposium: Metastatic Colorectal Cancer-State of the Science. Chicago, IL.
- 2014 Northwestern University Hematology/Oncology Grand Rounds: Achieving Health Equity in Colorectal Cancer: A Call to Action. Chicago, IL.

National/International

Health Disparities

- 2006 American Cancer Society Disparities Policy Forum. Reducing Health Disparities in Oncology: Pick the Low Hanging Fruit. Washington, DC.
- 2008 Center For Population Health and Health Disparities Investigator's Meeting: Understanding Differences in the Receipt and Completion of Adjuvant Chemotherapy between African Americans and Whites. Bethesda, MD.
- 2008 Society for Epidemiologic Research Meeting. Breast Cancer Disparities: Solving the Rubik's Cube. Chicago, IL.
- 2008 CALGB Fall Group Meeting: Toward an Understanding Of Racial Disparities in Metastatic Breast Cancer: Prospective Data Collection in CALGB 40502. Tampa, FL.
- 2010 Biological, Clinical and Psychosocial Correlates at the Interface of Aging & Cancer Research Conference: Age, Race and Clinical Trial Enrollment: We Have Met the Enemy, and it is Us. Chicago, IL.
- 2010 Sixth Annual Oncology Congress Keynote Address: Understanding and Reducing Health Disparities in Colorectal Cancer. San Francisco, CA.
- 2010 CALGB Fall Group Meeting: Improving Minority Accrual to CALGB Clinical Trials: What Are the Barriers and What are the Solutions? Miami, FL.
- 2012 University of Wisconsin-Madison, Medical Grand Grounds (Chief Resident's Dream Speaker Series). Understanding and Reducing Disparities in Colorectal Cancer: A Call to Action. Madison, WI.
- 2012 ASCO 2012 Clinical Science Symposium: Optimizing Delivery of High-Quality Cancer Care: Disparities in Cancer Care and Outcomes: The Search for Causality. Chicago, IL.
- 2012 AACR Science of Health Disparities Meeting: Reducing Disparities in Colorectal Cancer: A Call To Action. Chicago, IL
- 2012 Alliance Fall Group Meeting: Standardized Sociodemographic and Psychosocial Questionnaires for Alliance Trials. Chicago, IL.
- 2012 City College of New York/Memorial Sloan Kettering Cancer Center RCMI Translational Health Disparities Seminar-Achieving Health Equity in Colorectal Cancer: A Call to Action.
- 2013 ASCO 2013 Education Session (Chair): Racial and Ethnic Disparities in Colorectal Cancer: Identifying the Problem and Finding Solutions.
- 2014 Breast Cancer Research Foundation Disparities in Breast Cancer Care and Research Workshop: Lessons from the ASCO/AACR/ACS/NCI Cancer Disparity Think Tank. New York, NY
- 2017 Yale Law School Forum on Cancer Policy-Achieving Health Equity in Cancer: A Fixable Problem. New Haven, CT
- 2019 American Society of Clinical Oncology: Post Plenary Discussant on Medicaid and Cancer Disparties. Chicago, IL
- 2021 Hawaii Medical Oncology Society: The Past Cannot Be Prologue: NGS and Cancer Disparities, Virtual Health Policy
- 2011 National Cancer Institute CCOP/MBCCOP Research Base Meeting: The Accountable Care Act and Cancer Health Disparities: Now What? Bethesda, MD.
- 2014 ASCO 2014 Education Session (Chair): Health Care in America in 2014: Current and Future Implications of the Patient Protection and Affordable Care Act. Chicago, IL.
- 2014 Best of ASCO Chicago 2014: Implications of the Affordable Care Act on Oncology Practice and Health Equity: The Times They are a Changing. Chicago, IL.
- 2014 National Black Caucus of State Legislators and National Hispanic Caucus of State Legislators Annual Meeting: Quality Based Payment Reform of Oncology Care. Chicago, IL.

2014 NCCS Cancer Policy Roundtable: The Physician Payments Sunshine Act and Its Impact on Cancer Care, Research, and Education. Washington, DC.

2015 BMT Tandem Scientific Meeting: The governmental view of cancer care: ASCO statement on Medicaid reform and how it may impact care delivery for HSCT patients. San Diego, CA

2015 ASCO Annual Meeting: ASP+6 (4.3)-Is It Under Political Threat? Chicago, IL.

2015 ASCO Annual Meeting Highlights of the Day: Health Services Research Highlights: Bridging the Gap to Payment Reform. Chicago, IL.

2015 Best of ASCO 2015: The Oncology Reimbursement Landscape: The Times They are a Changin'. San Francisco, CA.

2015 USC Schaeffer Center and The Hill: The Future of Specialty Drugs: A Policy Discussion on Treatments and Affordability. Washington, DC

2015 Roswell Park Cancer Center: The Oncology Reimbursement Landscape: The Times They are a Changin'. Buffalo, NY

2016 Tennessee Oncology Society Annual Meeting: The Oncology Reimbursement Landscape: The Times They are a Changin'. Nashville, TN.

2016 ASCO Annual Meeting: MACRA Town Hall: Effects on your Medicare Reimbursement. Chicago, IL

2016 Best of ASCO: MACRA Town Hall: Effects on your Medicare Reimbursement. Chicago, IL

2016 Wisconsin Medical Oncology Society Annual Meeting: MACRA: A Brave New World. Milwaukee, WI.

2017 Indiana Medical Oncology Society Annual Meeting: MACRA: A Brave New World. Fort Wayne, IN.

2017 ASCO Annual Business of Oncology Meeting: The Bundle Jungle. Orlando, FL.

2017 ASCO Quality of Care Symposium: The OCM Journey: One Practice's Experience-Warts and All. Orlando, FL.

2017 American College of Physicians Annual Meeting: The OCM Journey: One Practice's Experience-Warts and All. San Diego, CA.

2017 American Society of Clinical Oncology Annual Meeting Poster Discussion Section Discussant: Opportunities for Closing the Gap in Cancer Health Disparities. Chicago, IL

2017 American Society of Clinical Oncology Annual Meeting Annual Town Hall: Practice Realities in a Shifting Policy Landscape

2017 American Society of Clinical Oncology Best of ASCO Boston: Practice Realities in a Shifting Policy Landscape

2017 Oregon/Washington State Medical Society Annual Meeting: The OCM Journey: One Practices Experiences-Warts and All. Willamette Valley, OR.

2017 Northern New England Medical Oncology Society Annual Meeting Elaine Towels Lecture: Achieving Value in Oncology

2018 University of North Carolina Hematology Oncology Ground Rounds: Achieving Value in Oncology: A 5000 to 50 Foot View. Chapel Hill, NC

2018 Society of Surgical Oncology Annual Meeting: Bundled Payments in Surgical Oncology: The Medical Oncology/ASCO Perspective

2018 ASCO and Best of ASCO National Meeting: Legislative and Regulatory Update: Practice Management and Policy Issues

2018 Colorado Medical Society: Achieving Value in Oncology: A 5000 to 50 Foot View. Denver, CO.

2019 American Society of Clinical Oncology: ASCO/ESMO Joint Session. The Challenges to Access in the United States. Chicago, IL.

2019. Hematology/Oncology Pharmacy Association: Value Based Payment in Oncology: Where Should We Be Going Next? Washington, DC.

2019 Hematology/Oncology Pharmacy Association: Measuring Quality in Oncology. Washington, DC.

2019 ECCO 2019 European Cancer Summit: Changing Payment Systems to Achieve the Triple Threat: Better Health, Better Care, Lower Costs. Belgium, Brussels.

GI Oncology

2007 Advances at the Forefront: Translational Medicine At the Bedside: Colorectal Cancer: Progress and Promise for the 21st Century. Napa, CA.

2011 ASCO Annual Meeting-Meet the Professor: Which Chemotherapy and When: Understanding the Timing and Type of Chemotherapy in Patients with Rectal Cancer. Chicago, IL.

2011 Japan Society of Clinical Oncology Annual Meeting: Stage II Colon Cancer: Toward and Individualized Approach. Nagayo, Japan.

2011 APAO Annual Meeting: Best of ASCO 2011-Updates in GI Oncology: Clarifying the Field.

Chicago, IL.
2015 Ecuadorian GI Society and University of Cuenca-State of the Science in Colorectal Cancer. Cuenca, Ecuador.
2015 Montana State Oncology Society: Therapy for Metastatic Colorectal Cancer: State of the Science. Big Sky, MT.
2015 ASCRS Annual Scientific Meeting-Role of Neoadjuvant and Adjuvant Therapy in Rectal Cancer. Boston, MA.
2015 American College of Surgeons Clinical Congress- Radiation and Chemotherapy for Locally Advanced Rectal Cancer: Does Every Patient Need Both? Chicago, IL.
2018 Society of Surgical Oncology Annual Meeting: "Am I a Candidate for Personalized Treatment?" Novel Targeted Therapies for Mutated Colorectal Cancers. Chicago, IL.
2018 Peeking Union Medical Center Hospital Pancreatic Disease Symposium: Pancreatic Neuroendocrine Tumors: The Science and Art of Treatment. Beijing, China.
2020 Thai Society of Clinical Oncology: Precision Medicine in GI Oncology, Virtual
2021 Japanese Society of Clinical Oncology: Precision Medicine in Oncology: A Colorectal Cancer Journey, Virtual